Status:
UNKNOWN
Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma
Lead Sponsor:
Zhongnan Hospital
Conditions:
Glioma
Glioblastoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
TTFields has been approved by the FDA for the treatment of patients with glioblastoma multiforme. However, the clinical effect and safety of radiotherapy concurrent of TTFields is not definite. In thi...
Detailed Description
the investigators plan to recruit 30 patients to evaluate the efficacy and safety of this strategy.
Eligibility Criteria
Inclusion
- performance status of 0-1 (Eastern Cooperative Oncology Group performance status)
- histologically confirmed glioblastoma
- no cerebrospinal fluid and distant metastatic disease.
Exclusion
- with a history of brain radiotherapy
- severe hepatic and renal dysfunction
Key Trial Info
Start Date :
June 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 19 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04902586
Start Date
June 19 2021
End Date
July 19 2022
Last Update
May 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan hospital
Wuhan, Hubei, China